• Explore /
  • Poster
  • / A phase II study of tislelizumab (T) monotherapy as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC).

A phase II study of tislelizumab (T) monotherapy as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC).

Abstract Poster

Authors

null

Jiwei Huang

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Jiwei Huang , Xinyun Cai , Wen Kong , Jin Zhang , Yonghui Chen , Haige Chen , Wei Xue

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04672330

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 591)

DOI

10.1200/JCO.2024.42.4_suppl.591

Abstract #

591

Poster Bd #

F18

Abstract Disclosures

Similar Posters

First Author: Michal Sternschuss

First Author: Yige Bao

First Author: Zongren Wang

First Author: Jhe-Cyuan Guo